Its guidance for 13% growth in underlying earnings before interest, tax, depreciation and amortisation (EBITDA), and almost double-digit growth in earnings-per-share, was affirmed in late May. However, there’s been a little weakness in the share price recently, which could be due to company expectations that EBITDA and profit will temporarily grow at a slower rate than in recent years. Shareholders with much shorter time frames never like to read of ‘slowing’ growth, which is why it’s important to take the longer view. With 2019 expected to seeaccelerating EBITDA and profit growth, now is a good time to pick up a few more shares.
- Forums
- ASX - By Stock
- Very Soon Going up past 3.20
Its guidance for 13% growth in underlying earnings before...
-
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ARQ (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Andy Udell, CCO
Andy Udell
CCO
SPONSORED BY The Market Online